Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005685 | 0.90 | RORC (0.41) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL2000557 | 0.88 | RORC (0.42) | RORCJAK2TYK2CPT1ACYP11B1 | |
| SCHEMBL1999742 | 0.88 | CPT1A (0.43) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL2005473 | 0.88 | RORC (0.41) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL12570127 | 0.87 | RORC (0.39) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL2002539 | 0.84 | RORC (0.44) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL1997586 | 0.83 | GPBAR1 (0.31) | RORC | |
| SCHEMBL1999356 | 0.80 | RORC (0.43) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL2010709 | 0.80 | CPT1A (0.42) | RORCCPT1ACYP11B1MAPTNR1H3 | |
| SCHEMBL12625796 | 0.79 | RORC (0.41) | RORCCPT1ANR1H3NR1H2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | RORC 122/4885JAK2 410/4885TYK2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.